Media
Uganda’s dual approach to tackle type 1 diabetes in children and young people
15 May 2025
Date
13 May 2025
Report calls for improved access to type 1 diabetes care in LMICs
Navlin Daily covers the Access to Medicine Foundation’s newly released report, which highlights critical gaps in diabetes care faced by children and young people (CYP) in low- and middle-income countries (LMICs).
The article refers to the Access to Medicine Foundation’s recent report, which analyses 11 initiatives providing diabetes care for children and young people (CYP) living with type 1 diabetes (T1D) in low- and middle-income countries. These initiatives are supported by the world’s three largest insulin manufacturers – Eli Lilly and Company, Novo Nordisk, and Sanofi – as well as biosimilar producer Biocon Limited, through donations of insulin, delivery devices, and financial contributions.Â
The article then highlights a key finding of the report: over 50% of LMICs are covered by these company-backed initiatives providing diabetes care to CYP with T1D. However, despite this coverage, only a small fraction of CYP in these regions are reached.Â
It also outlines the report’s five practical recommendations for pharma companies: scaling up initiatives, broadening product ranges, improving care sustainability, addressing affordability gaps, and strengthening data-driven policies and access strategies.Â
